Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BHV-7000 in Inherited Erythromelalgia
NCT07262268Phase 1Active, not recruiting
- Sponsor
- Biohaven Ltd.
- Start
- Jan 2026
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in erythromelalgia comparing BHV-7000 with Placebo (2 arms). Primary endpoint: Mean of the daily average maximum pain intensity scores. Started Jan 2026; status: active, not recruiting.
02
Drugs
opakalim
03
Conditions
erythromelalgia
Beyond the preview
Go deeper on NCT07262268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07262268.